Progression types after antiangiogenic therapy are related to outcome in recurrent glioblastoma

Objective: This retrospective study analyzed whether the type of radiologic progression, classified according to contrast enhancement on MRI T1-weighted sequences and changes in T2-hyperintense signal, is relevant for outcome in patients with progressive glioblastoma (pGB) treated with bevacizumab. Methods: MRI scans of 83 patients with pGB treated with bevacizumab were evaluated prior to and at disease progression. Based on initial decrease in and subsequent flare-up of contrast enhancement in T1 and 2 patterns of T2-hyperintense tumor progression, progression types (PTs) were categorized as cT1 flare-up, T2-diffuse, T2-circumscribed, or primary nonresponder. Overall survival (OS), survival from start of bevacizumab therapy (OS_Bev), survival after bevacizumab failure (OS_PostBev), time from initial diagnosis until initiation of bevacizumab therapy (StartBevT), and time to bevacizumab progression were evaluated using Kaplan-Meier curves, log-rank test, and Cox regression analyses. Results: The time observed for development of a T2-diffuse (n = 15) or a cT1 flare-up (n = 35) progression was longer than for progression in primary nonresponders (n = 16) or T2-circumscribed progression (n = 17). The T2-diffuse PT showed longer OS, OS_Bev, OS_PostBev, and StartBevT compared to the other PTs. Postprogression therapy tended to be relevant only for patients with a T2-circumscribed PT. Conclusions: Radiologic PTs following bevacizumab treatment failure show differences in time to development and are related to outcome. We therefore hypothesize that these PTs reflect a different glioma biology, including differential resistance mechanisms to bevacizumab, and may be associated with different responses to postprogression therapy.

[1]  J. D. de Groot,et al.  Mediators of Glioblastoma Resistance and Invasion during Antivascular Endothelial Growth Factor Therapy , 2009, Clinical Cancer Research.

[2]  John A Butman,et al.  Phase II trial of single-agent bevacizumab followed by bevacizumab plus irinotecan at tumor progression in recurrent glioblastoma. , 2009, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[3]  H. Kostron,et al.  O-(2-18F-Fluoroethyl)-L-Tyrosine PET Predicts Failure of Antiangiogenic Treatment in Patients with Recurrent High-Grade Glioma , 2011, The Journal of Nuclear Medicine.

[4]  R. Mirimanoff,et al.  Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma. , 2005, The New England journal of medicine.

[5]  Matthew S. Brown,et al.  Recurrent glioblastoma multiforme: ADC histogram analysis predicts response to bevacizumab treatment. , 2009, Radiology.

[6]  M S Brown,et al.  Patterns of progression in patients with recurrent glioblastoma treated with bevacizumab , 2011, Neurology.

[7]  Paul S Mischel,et al.  Quantitative volumetric analysis of conventional MRI response in recurrent glioblastoma treated with bevacizumab. , 2011, Neuro-oncology.

[8]  P. Wen,et al.  Role of a second chemotherapy in recurrent malignant glioma patients who progress on bevacizumab. , 2009, Neuro-oncology.

[9]  Susan M. Chang,et al.  Updated response assessment criteria for high-grade gliomas: response assessment in neuro-oncology working group. , 2010, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[10]  Dushyant V. Sahani,et al.  Biomarkers of response and resistance to antiangiogenic therapy , 2009, Nature Reviews Clinical Oncology.

[11]  T. Mikkelsen,et al.  Efficacy, safety and patterns of response and recurrence in patients with recurrent high-grade gliomas treated with bevacizumab plus irinotecan , 2009, Journal of Neuro-Oncology.

[12]  Y. Kienast,et al.  Bevacizumab Has Differential and Dose-Dependent Effects on Glioma Blood Vessels and Tumor Cells , 2011, Clinical Cancer Research.

[13]  M. Westphal,et al.  Inhibition of glioma angiogenesis and growth in vivo by systemic treatment with a monoclonal antibody against vascular endothelial growth factor receptor-2. , 2001, Cancer research.

[14]  D. Sargent,et al.  Bevacizumab beyond first progression is associated with prolonged overall survival in metastatic colorectal cancer: results from a large observational cohort study (BRiTE). , 2008, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[15]  S. Heiland,et al.  Bevacizumab does not increase the risk of remote relapse in malignant glioma , 2011, Annals of neurology.

[16]  M. Chamberlain.  Role for cytotoxic chemotherapy in patients with recurrent glioblastoma progressing on bevacizumab: a retrospective case series , 2012, Expert review of neurotherapeutics.

[17]  G. Fuller,et al.  Tumor invasion after treatment of glioblastoma with bevacizumab: radiographic and pathologic correlation in humans and mice , 2010, Neuro-oncology.

[18]  Y. Benjamini,et al.  Controlling the false discovery rate in behavior genetics research , 2001, Behavioural Brain Research.

[19]  Tracy T Batchelor,et al.  Bevacizumab salvage therapy following progression in high-grade glioma patients treated with VEGF receptor tyrosine kinase inhibitors. , 2010, Neuro-oncology.

[20]  P. Kelly,et al.  Antiangiogenic therapy using bevacizumab in recurrent high-grade glioma: impact on local control and patient survival. , 2009, Journal of neurosurgery.

[21]  William D. Dunn,et al.  MR imaging predictors of molecular profile and survival: multi-institutional study of the TCGA glioblastoma data set. , 2013, Radiology.

[22]  M. Mrugala,et al.  Bevacizumab for recurrent malignant gliomas: efficacy, toxicity, and patterns of recurrence. , 2009, Neurology.

[23]  David Gutman,et al.  Genomic mapping and survival prediction in glioblastoma: molecular subclassification strengthened by hemodynamic imaging biomarkers. , 2013, Radiology.

[24]  M. Weller,et al.  Patterns of Progression in Malignant Glioma Following Anti-VEGF Therapy: Perceptions and Evidence , 2011, Current neurology and neuroscience reports.

[25]  P. Carmeliet,et al.  Molecular mechanisms and clinical applications of angiogenesis , 2011, Nature.

[26]  L. Stalpers,et al.  Concerns about anti-angiogenic treatment in patients with glioblastoma multiforme , 2009, BMC Cancer.

[27]  S. Pastorino,et al.  Transdifferentiation of glioblastoma cells into vascular endothelial cells , 2011, Proceedings of the National Academy of Sciences.

[28]  Gabriele Bergers,et al.  Modes of resistance to anti-angiogenic therapy , 2008, Nature Reviews Cancer.

[29]  T. Taxt,et al.  Anti-VEGF treatment reduces blood supply and increases tumor cell invasion in glioblastoma , 2011, Proceedings of the National Academy of Sciences.

[30]  P. Wen,et al.  Novel anti-angiogenic therapies for malignant gliomas , 2008, The Lancet Neurology.